IS7097A - Lyfjablanda til að gefa fúlvestrant í vöðva - Google Patents

Lyfjablanda til að gefa fúlvestrant í vöðva

Info

Publication number
IS7097A
IS7097A IS7097A IS7097A IS7097A IS 7097 A IS7097 A IS 7097A IS 7097 A IS7097 A IS 7097A IS 7097 A IS7097 A IS 7097A IS 7097 A IS7097 A IS 7097A
Authority
IS
Iceland
Prior art keywords
filvestrant
intramuscular
administration
medicinal product
medicinal
Prior art date
Application number
IS7097A
Other languages
English (en)
Inventor
Kay Cahill Julie
Richard Gellert Paul
Marshall Irving Alan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0116619.8A external-priority patent/GB0116619D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS7097A publication Critical patent/IS7097A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
IS7097A 2001-07-07 2004-01-05 Lyfjablanda til að gefa fúlvestrant í vöðva IS7097A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0116619.8A GB0116619D0 (en) 2001-07-07 2001-07-07 Formulation
US31571101P 2001-08-30 2001-08-30
PCT/GB2002/003092 WO2003006064A1 (en) 2001-07-07 2002-07-03 Pharmaceutical formulation for the intramuscular administration of fulvestrant

Publications (1)

Publication Number Publication Date
IS7097A true IS7097A (is) 2004-01-05

Family

ID=26246290

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7097A IS7097A (is) 2001-07-07 2004-01-05 Lyfjablanda til að gefa fúlvestrant í vöðva

Country Status (15)

Country Link
EP (1) EP1406662A1 (is)
JP (1) JP2004534093A (is)
CN (1) CN1553815A (is)
AR (1) AR037138A1 (is)
BR (1) BR0210898A (is)
CA (1) CA2453111A1 (is)
CO (1) CO5560585A2 (is)
HU (1) HUP0400115A3 (is)
IL (1) IL159576A0 (is)
IS (1) IS7097A (is)
MX (1) MXPA04000028A (is)
NO (1) NO20040047L (is)
PL (1) PL367624A1 (is)
RU (1) RU2004102393A (is)
WO (1) WO2003006064A1 (is)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
EP2417975A4 (en) 2009-08-31 2012-11-14 Xi An Libang Medical Technology Co Ltd FULVESTRANT NANOPERLENES / MICROPERLES AND MANUFACTURING METHOD AND USE
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
CN102600064A (zh) * 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
CN102600065B (zh) * 2012-03-31 2014-08-13 莱普德制药有限公司 一种氟维司群或其衍生物油性制剂及其制备方法
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
EP3441073B1 (en) 2016-04-06 2022-02-23 FUJIFILM Corporation Medicinal composition comprising fulvestrant
CA3022834A1 (en) * 2016-05-06 2017-11-09 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
JP6611932B2 (ja) 2016-05-31 2019-11-27 富士フイルム株式会社 医薬組成物
AU2018366212A1 (en) * 2017-11-08 2020-05-14 Eagle Pharmaceuticals, Inc Fulvestrant formulations and methods of their use
WO2019113361A1 (en) * 2017-12-07 2019-06-13 Nevakar Inc. Concentrated fulvestrant compositions
CN111465398A (zh) * 2018-01-31 2020-07-28 富士胶片株式会社 注射用制剂的制造方法
CN111481559B (zh) * 2019-01-25 2021-10-08 江苏恒瑞医药股份有限公司 一种高浓度的氟维司群组合物及其制备方法
JP2023504867A (ja) * 2019-12-11 2023-02-07 上海博志研新薬物技術有限公司 フルベストラント医薬組成物、その調製方法及び応用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
GB9525194D0 (en) * 1995-12-12 1996-02-07 Zeneca Ltd Pharmaceutical composition
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy

Also Published As

Publication number Publication date
AR037138A1 (es) 2004-10-27
BR0210898A (pt) 2004-06-22
CA2453111A1 (en) 2003-01-23
MXPA04000028A (es) 2004-05-21
WO2003006064A1 (en) 2003-01-23
CN1553815A (zh) 2004-12-08
RU2004102393A (ru) 2005-03-27
IL159576A0 (en) 2004-06-01
PL367624A1 (en) 2005-03-07
EP1406662A1 (en) 2004-04-14
HUP0400115A2 (hu) 2004-06-28
CO5560585A2 (es) 2005-09-30
JP2004534093A (ja) 2004-11-11
NO20040047L (no) 2004-02-23
HUP0400115A3 (en) 2005-11-28

Similar Documents

Publication Publication Date Title
NO20033384D0 (no) Farmasöytisk formulering
IS6994A (is) Arípíprazóllausn til gjafar um munn
NO20033556D0 (no) Farmasöytiske preparater
NO20033785D0 (no) Farmasöytisk formulering
DE60220661D1 (de) Transdermales pflaster zur verabreichung von fentanyl
IS6986A (is) Lyfjasamsetning í vökvaformi
ITTO20010008A0 (it) Formulazione farmaceutica
FI20011478A (fi) Farmaseuttinen koostumus
EE05020B1 (et) Glburiidi ravimkoostis
NO20035627D0 (no) Farmasöytisk formulering
IS7097A (is) Lyfjablanda til að gefa fúlvestrant í vöðva
IS7051A (is) Lyfjasamsetningar
FI20011889A (fi) Menetelmä ksylitolin valmistamiseksi
NO20034556D0 (no) Imidazotriazinon-holdige sammensetninger for nasal administrering
DE60203537D1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
NO20042640L (no) Fremgangsmate for fremstilling av ekinocandinderivater
DK1475379T3 (da) Anvendelse af scopinesterderivater til fremstilling af lægemidler
DK1385512T3 (da) Anvendelse af pyridoindolonderivater til fremstilling af anticancerlægemidler
FI20010892A (fi) Menetelmä ksylitolin valmistamiseksi
FI20012242A0 (fi) Uudet farmaseuttiset yhdisteet
NO20041236L (no) Farmasoytisk formulering
NO20040312L (no) Fremgangsmåte for fremstilling av farmasøytiske preparater
IT1320253B1 (it) Composizione farmaceutica per il trattamento della malaria.
SE0102572D0 (sv) Pharmaceutical formulation